KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $142.8 million.

  • Halozyme Therapeutics' Cash & Current Investments fell 7603.99% to $142.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $142.8 million, marking a year-over-year decrease of 7603.99%. This contributed to the annual value of $142.8 million for FY2025, which is 7603.99% down from last year.
  • As of Q4 2025, Halozyme Therapeutics' Cash & Current Investments stood at $142.8 million, which was down 7603.99% from $702.0 million recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Cash & Current Investments registered a high of $815.9 million during Q3 2021, and its lowest value of $142.8 million during Q4 2025.
  • Moreover, its 5-year median value for Cash & Current Investments was $538.6 million (2024), whereas its average is $527.0 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 13533.48% in 2021, then plummeted by 7603.99% in 2025.
  • Halozyme Therapeutics' Cash & Current Investments (Quarter) stood at $740.9 million in 2021, then tumbled by 51.03% to $362.8 million in 2022, then fell by 7.39% to $336.0 million in 2023, then skyrocketed by 77.4% to $596.1 million in 2024, then plummeted by 76.04% to $142.8 million in 2025.
  • Its Cash & Current Investments stands at $142.8 million for Q4 2025, versus $702.0 million for Q3 2025 and $548.2 million for Q2 2025.